Table 1.
Correlations between Ribonucleotide Reductase Subunit M2 Expression and Clinicopathologic Features in 259 Patients with Hepatocellular Carcinomas
| Variable | No. | High RRM2 expression, no. (%) | p-value |
|---|---|---|---|
| Age, yr | |||
| ≤55 | 154 | 123 (79.9) | 0.547 |
| >55 | 105 | 87 (82.9) | |
| Gender | |||
| Female | 48 | 35 (72.9) | 0.110 |
| Male | 211 | 175 (82.9) | |
| Tumor size, cm | |||
| ≤5.0 | 163 | 133 (81.6) | 0.783 |
| >5.0 | 96 | 77 (80.2) | |
| Edmondson grade | |||
| I | 24 | 19 (79.2) | 0.184 |
| II | 178 | 140 (78.7) | |
| III | 57 | 51 (89.5) | |
| Microvascular invasion | |||
| (−) | 114 | 87 (76.3) | 0.083 |
| (+) | 145 | 123 (84.8) | |
| Major portal vein invasion | |||
| (−) | 247 | 200 (81.8) | 1.000 |
| (+) | 12 | 10 (83.3) | |
| Intrahepatic metastasis | |||
| (−) | 195 | 155 (79.5) | 0.253 |
| (+) | 64 | 55 (85.9) | |
| Multicentric occurrence | |||
| (−) | 247 | 202 (81.8) | 0.249 |
| (+) | 12 | 8 (66.7) | |
| AJCC T-stage | |||
| 1 | 110 | 86 (78.2) | 0.550 |
| 2 | 99 | 83 (83.8) | |
| 3 | 44 | 35 (79.5) | |
| 4 | 6 | 6 (100.0) | |
| BCLC stage | |||
| 0–A | 141 | 113 (80.1) | 0.965 |
| B | 104 | 85 (81.7) | |
| C | 14 | 12 (85.7) | |
| Albumin level, g/dL | |||
| >3.5 | 232 | 185 (79.7) | 0.107 |
| ≤3.5 | 27 | 25 (92.6) | |
| AFP level, ng/mL* | |||
| ≤200 | 151 | 127 (84.1) | 0.136 |
| >200 | 98 | 75 (76.5) | |
| Etiology | |||
| Nonviral | 36 | 24 (66.7) | 0.035 |
| HBV | 198 | 167 (84.3) | |
| HCV | 25 | 19 (76.0) | |
| Liver cirrhosis | |||
| (−) | 129 | 98 (76.0) | 0.036 |
| (+) | 130 | 112 (86.2) | |
| Early recurrence (≤2 yr) | |||
| (−) | 119 | 87 (73.1) | 0.004 |
| (+) | 140 | 123 (87.9) | |
| Late recurrence (>2 yr) | |||
| (−)† | 74 | 54 (73.0) | 0.966 |
| (+) | 45 | 33 (73.3) | |
RRM2, ribonucleotide reductase subunit M2; AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus.
*
Data for 10 patients were unavailable;
†
No early or late recurrence.